Molly Harper has over 20 years of experience focusing on commercial strategy and leadership at life sciences companies of all sizes. Since October 2021, Ms. Harper has served as Chief Business Officer for Synlogic, Inc. a clinical-stage biotechnology company bringing the transformative potential of synthetic biology to medicine. Ms. Harper joined Synlogic from Relmada Therapeutics, Inc., where she was most recently Executive Vice President of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, equity research at UBS Warburg and strategy consulting at The Wilkerson Group/IBM.
Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from The Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held AI oncology pathology company.